CDK6 and chronic myelogenous leukemia, BCR-ABL1 positive: MiR-300-induced loss of cyclin D2/cyclin-dependent kinase 6 (CDK6), which occurs at low levels of MIR300 expression, likely represents the mechanism by which miR-300 antiproliferative activity contributes to CML stemness.